Phylo

Phylo develops collaborative AI agents designed for biologists to accelerate discoveries in biomedical research. The company offers Biomni Lab, an integrated biology environment that serves as a unified workspace where biologists collaborate with AI agents to conduct research with rigor and at scale. The platform features over 100 pre-built agentic workflows across the biopharma value chain, with deterministic pipelines for reproducible results. Phylo's agents clarify questions before starting, check reasoning against a biology knowledge graph, and review their own work with traceable references. The platform is model-agnostic, dynamically matching tasks to the best available model, and is private by design with single-tenant cloud infrastructure. Phylo is ISO 27001 certified and SOC 2 Type 2 compliant, trusted by leading pharma, biotech, and academic labs. Founded in 2020 and headquartered in Boston, Massachusetts, Phylo has raised $13.5 million in Seed funding co-led by Andreessen Horowitz and Menlo Ventures, with participation from Zetta Venture Partners, Conviction, and SV Angel.

Life Sciences Tech > Research & Development > Drug Discovery > Cheminformatics > Lead Discovery > AI Based

College Wise > Harvard University, New York University, Stanford University